X

Fermenta Biotech Ltd Stock Analysis

Small Cap
Evaluated by 266 users | BSE: 506414 | NSE: |
Pharmaceuticals & Drugs
DIL Ltd. formerly Duphar-Interfran Limited is an Indian public listed company located at Thane, India. Founded in 1951 by Late Dr. D V K Raju in the name of International Franchises Private Limited. DIL has built successful partnerships with leading multinational companies for over 53 years....

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20
Return on Capital Employed 26.08%15.26%5.49%1.32%0.62%-5.78%-10.12%-7.3%39.24%15.56%
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 32.327.61815.213.56.15.512.5405301
Y-o-Y Gr. Rt.--14.6%-34.6%-15.7%-11%-54.6%-10.1%126.6%3134.8%-25.7%
Adjusted EPS (Rs.) 7.925.391.950.510.27-3.29-6.64-7.2342.0421.81
Y-o-Y Gr. Rt.--31.9%-63.8%-73.9%-47.1%-1318.5%NANANA-48.1%
Book Value per Share (Rs.) 32.1134.5434.333.8433.630.0332.5623.5286.69106.26
Adjusted Net Profit 21.814.85.41.40.7-9.1-18.3-19.911662.9
Net Op. Cash Flow (Rs. Cr.) -3.231.4111.9-0.4-5-9.11.390.529.8
Debt to Cash Flow from Ops -1.740.190.513.72-93.27-11.03-4.85107.912.317.38
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Fermenta Biotech Ltd. should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  9 yrs 5 yrs 3 yrs 1 yr
Net Sales 28.1%85.9%279%-25.7%
Adjusted EPS 11.9%140.7%NA-48.1%
Book Value per Share 14.225.948.322.6
Share Price 24.1% 39.9% 0.4% 5.2%
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20
Return on Equity (%) 26.9816.165.661.510.8-10.34-21.22-25.873.6422.39
Operating Profit Margin (%) 69.8973.5150.5228.2621.53-98.92-153.98-26.5135.4723.03
Net Profit Margin (%) 67.5153.7529.759.325.51-147.55-331.29-159.1528.5920.94
Debt to Equity 0.060.060.060.280.390.660.492.210.870.72
Working Capital Days 1651803414244398661,020520111304
Cash Conversion Cycle -4-1-3-8-15-24-16-2035129
Entity Percentage Holding
Promoters 59.44%
Institutions 0.49%
Non-Institutions 40.07%
Others 0.01%
Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)
Data is not available for this company.

The 5-year analysis of Fermenta Biotech Ltd's performance infers:

Fermenta Biotech Ltd earnings have grown by 140.7%, whereas share price has appreciated 39.9% CAGR over the past five years, indicating the company's share price is likely undervalued. However, for specific investment actions please connect with your investment advisor.

We analysed the performance of Fermenta Biotech Ltd share prices over the last 10 years. Here is what we found out:

Fermenta Biotech Ltd share price has appreciated 24.5% annually over the past ten years.

DIL Ltd. formerly Duphar-Interfran Limited is an Indian public listed company located at Thane, India. Founded in 1951 by Late Dr. D V K Raju in the name of International Franchises Private Limited. DIL has built successful partnerships with leading multinational companies for over 53 years. The name of the company was then changed to ‘Crookes Interfran Limited’ and then in 1971 the name was changed to ‘Duphar Interfran Ltd.’. In the year 1976, the

DIL Ltd. formerly Duphar-Interfran Limited is an Indian public listed company located at Thane, India. Founded in 1951 by Late Dr. D V K Raju in the name of International Franchises Private Limited. DIL has built successful partnerships with leading multinational companies for over 53 years. The name of the company was then changed to ‘Crookes Interfran Limited’ and then in 1971 the name was changed to ‘Duphar Interfran Ltd.’. In the year 1976, the company’s equity shares were listed on the Stock Exchange of Bombay (BSE). In 2000, the company demerged its pharmaceutical business into a new company called Duphar Pharma India Ltd. (currently known as Solvay Pharma India Ltd.) which issued to the shareholders of Duphar Interfran Ltd., 2 equity shares of Duphar Pharma India Ltd. for every 1 share held in Duphar Interfran Ltd. by the shareholders at that time, while retaining their original share in Duphar Interfran Ltd. The name of the company was then changed to DIL Limited.

Currently, DIL is engaged in the business of research support services through its subsidiary Research Support International Ltd. (RSIL), manufacture and marketing of enzymes and chemicals through its subsidiary Fermenta Biotech Ltd. (FBL), entertainment through its subsidiary White Stripes Entertainment Ltd. (WSEL) and manufacture and marketing of levitation technology and wheel chairs through its Joint Venture company, being set up in the Czech Republic.

With the growing global need for newer drugs and for research, DIL, with its capabilities, becomes a preferred partner for undertaking contract research and custom synthesis.

Specializing in synthesis of fine organic compounds, chiral building blocks and Intermediates, their expertise include developing small size, aromatic & non-aromatic, functionalized heterocycles, enzyme mediated asymmetric synthesis of hydroxyesters, protection of amino acids at amino and carboxyl functionalities and synthesis of compounds having peptide linkage.

From its fully-equipped and modern facilities, the multi-cultural team at DIL strives to offer the best services in organic synthesis and industrial biotechnology.  Qualified synthetic chemists develop and produce tailor-made compounds (Gms to multi-kegs) for the pharmaceutical and biotechnology industries. Their services cover both individual projects, as well as working exclusively as permanent team members for clients.

Offering expertise on both short and long-term projects, DIL seamlessly blends in as an extension of the client company, offering flexible and integrated services, made to measure solutions, cost-effective and on-time service accelerating drug discovery and development – backed by the assurance of confidentiality.

With all this, DIL enhances and adds value to the client’s research program. DIL is a public listed company delivering reliable services to the pharmaceutical and biotechnology industries. Tucked away in a quiet and verdant niche in Thane, (32 km. away from Mumbai), and spread over 28,000 sq mts of land, is where it all happens.

Business area of the company:

Currently, DIL is engaged in the business of research support services through its subsidiary Research Support International Ltd. (RSIL), manufacture and marketing of enzymes and chemicals through its subsidiary Fermenta Biotech Ltd. (FBL), entertainment through its subsidiary White Stripes Entertainment Ltd. (WSEL) and manufacture and marketing of levitation technology and wheel chairs through its Joint Venture company, being set up in the Czech Republic.

Milestones:

  • 1951 – 1963: Toll manufacturing for the pharmaceutical and cosmetics industries.
  • 1963: The company established a JV with Philips Duphar for the manufacture and marketing of pharmaceutical products in India.
  • 1976: DIL was listed on the Bombay Stock Exchange.
  • 1980: Philips Duphar was taken over by Solvay Pharmaceuticals.
  • 1986: Fermenta Biotech Ltd. was founded as a subsidiary company to complement and segregate DIL’s capabilities in biotechnology.
  • 1987: Fundamental research was initiated as part of Solvay’s research efforts. A full-fledged laboratory was set up as per GLP requirements and accredited by the Department of Scientific & Industrial Research.
  • 1995: ‘Crocin’, which went on to become the most popular brand of paracetamol in India, was divested to SmithKline Beecham.
  • 2000: The company realigned its business to focus sharply and exclusively on custom synthesis and process R&D by de-merging its pharmaceutical formulation business in favour of Solvay.

 

Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback